Top Stories
Top Stories
Market Insider

After-hours buzz: HPE, TSCO, JUNO, SAGE & more

Getty Images

Here are the companies making headlines after the bell Wednesday:

Hewlett Packard Enterprise — the information technology company will spin off its software business and merge it with Micro Focus in a deal valued at about $8.8 billion. HPE will receive $2.5 billion in cash and its shareholders will own 50.1 percent of the new company.

HPE also reported third-quarter adjusted earnings that beat by 5 cents at 49 cents a share, while revenue of $12.2 billion missed forecasts of $12.65 billion. Shares were more than 2 percent lower in after-hours trade.

Tractor Supply — the retailer cut full-year revenue and earnings forecasts and gave third-quarter earnings per share guidance of 65 cents to 67 cents, below expectations of 72 cents.

Management cited challenges from declining comparable same-store sales in energy producing regions, negative sales pressure on agricultural communities from a continued decline in farm income and decreased demand for heating related products. Shares dropped more than 8 percent in extended-hours trade.

Dell Technologies — shares of the EMC/Dell tracking stock were more than 1 percent higher in after-hours trade following news that the company will repurchase $1 billion Class V shares. The stock closed 5.6 percent higher following the announced completion of Dell's $60 billion deal to acquire EMC, the largest technology merger in history.

Juno TherapeuticsScience Translational Medicine published a paper Wednesday that showed encouraging results for patients in a trial for a drug similar to one Juno is developing for a blood cancer treatment, the biopharmaceutical firm said. The study team for the paper included scientists from Juno, which provided one of the trial's sources of funding. Shares were more than 5.5 percent higher in after-hours trade.

SAGE Therapeutics — the biopharmaceutical firm said it has begun a public offering of $150 million of its common stock. The company, which develops medicines for nervous system disorders, also said it intends to give underwriters a 30-day option to purchase up to $22.5 million more of common stock offered in the public offering. Shares were more than 5.5 percent lower in after-hours trade.